State Board of Administration of Florida Retirement System Decreases Stock Holdings in Amgen, Inc. (NASDAQ:AMGN)

State Board of Administration of Florida Retirement System trimmed its position in Amgen, Inc. (NASDAQ:AMGN) by 5.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 826,047 shares of the medical research company’s stock after selling 45,225 shares during the quarter. State Board of Administration of Florida Retirement System owned 0.14% of Amgen worth $152,224,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Bray Capital Advisors boosted its stake in Amgen by 11.6% in the 2nd quarter. Bray Capital Advisors now owns 19,676 shares of the medical research company’s stock worth $3,626,000 after purchasing an additional 2,045 shares in the last quarter. Weaver Consulting Group bought a new position in Amgen in the 1st quarter worth about $239,000. CHICAGO TRUST Co NA boosted its stake in Amgen by 2.8% in the 2nd quarter. CHICAGO TRUST Co NA now owns 3,716 shares of the medical research company’s stock worth $685,000 after purchasing an additional 100 shares in the last quarter. Phocas Financial Corp. bought a new position in Amgen in the 4th quarter worth about $117,000. Finally, Calton & Associates Inc. boosted its stake in Amgen by 17.8% in the 2nd quarter. Calton & Associates Inc. now owns 1,770 shares of the medical research company’s stock worth $326,000 after purchasing an additional 268 shares in the last quarter. 78.01% of the stock is currently owned by institutional investors.

A number of brokerages recently issued reports on AMGN. BMO Capital Markets set a $230.00 price target on shares of Amgen and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Wells Fargo & Co upped their price target on shares of Amgen from $197.00 to $202.00 and gave the stock a “market perform” rating in a research note on Monday, August 12th. Royal Bank of Canada restated a “hold” rating on shares of Amgen in a research note on Sunday, August 11th. Morgan Stanley lowered their target price on shares of Amgen from $211.00 to $207.00 and set an “overweight” rating on the stock in a research note on Monday, July 15th. Finally, Piper Jaffray Companies set a $210.00 target price on shares of Amgen and gave the company a “buy” rating in a research note on Saturday, August 10th. Ten equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $212.94.

In other news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $187.58, for a total transaction of $375,160.00. Following the completion of the sale, the director now owns 16,336 shares of the company’s stock, valued at approximately $3,064,306.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director R Sanders Williams sold 425 shares of the company’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $183.04, for a total transaction of $77,792.00. Following the sale, the director now directly owns 16,336 shares of the company’s stock, valued at approximately $2,990,141.44. The disclosure for this sale can be found here. Insiders have sold a total of 4,425 shares of company stock valued at $804,312 in the last ninety days. Insiders own 0.25% of the company’s stock.

Shares of NASDAQ AMGN traded down $0.43 during midday trading on Tuesday, hitting $205.57. 919,849 shares of the company’s stock traded hands, compared to its average volume of 3,882,518. Amgen, Inc. has a 1 year low of $166.30 and a 1 year high of $211.90. The stock has a market capitalization of $122.35 billion, a price-to-earnings ratio of 14.28, a price-to-earnings-growth ratio of 2.39 and a beta of 1.19. The company has a debt-to-equity ratio of 2.58, a quick ratio of 2.60 and a current ratio of 2.89. The firm has a fifty day moving average of $185.13 and a 200 day moving average of $183.15.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, July 30th. The medical research company reported $3.97 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.58 by $0.39. Amgen had a net margin of 33.78% and a return on equity of 76.17%. The firm had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.67 billion. During the same quarter in the prior year, the firm earned $3.83 EPS. The business’s revenue for the quarter was down 3.1% compared to the same quarter last year. On average, equities analysts anticipate that Amgen, Inc. will post 14.25 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 6th. Stockholders of record on Thursday, August 15th will be given a dividend of $1.45 per share. This represents a $5.80 annualized dividend and a dividend yield of 2.82%. The ex-dividend date is Wednesday, August 14th. Amgen’s payout ratio is currently 40.28%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Read More: What is Considered a Good Return on Equity (ROE)?

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.